Alto Says Investors Use Hindsight In Suit Over Drug Trial
Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for...To view the full article, register now.
Already a subscriber? Click here to view full article